Kalaris Therapeutics (KLRS) Stock Price, News & Analysis

Company Overview

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Key Stats

• Today's Range: $3.81 to $4.18
• 50-Day Range: $2.27 to $4.68
• 52-Week Range: $2.14 to $24.15
• Volume: 214,177 shs
• Average Volume: 116,246 shs
• Market Capitalization: $72.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Buy

Kalaris Therapeutics Stock Analysis - MarketRank™

Kalaris Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 783rd out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.9 / 5
• Analyst Rating: Buy

Consensus Rating

Kalaris Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Downside Risk

Kalaris Therapeutics has a consensus price target of $3.00, representing about 22.9% downside from its current price of $3.89.

Amount of Analyst Coverage

Kalaris Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Kalaris Therapeutics has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.62% of the float of Kalaris Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Kalaris Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kalaris Therapeutics does not currently pay a dividend.

Dividend Growth

Kalaris Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.62% of the float of Kalaris Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Kalaris Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.95

News Sentiment

Kalaris Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Kalaris Therapeutics this week, compared to 1 article on an average week.

Search Interest

4 people have searched for KLRS on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Kalaris Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kalaris Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

74.99% of the stock of Kalaris Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

66.05% of the stock of Kalaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

KLRS Stock Analysis - Frequently Asked Questions

How have KLRS shares performed this year?

Kalaris Therapeutics' stock was trading at $2.79 at the start of the year. Since then, KLRS shares have increased by 39.4% and is now trading at $3.89.

How were Kalaris Therapeutics' earnings last quarter?

Kalaris Therapeutics Inc. (NASDAQ:KLRS) released its earnings results on Wednesday, August, 13th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.10.

Who are Kalaris Therapeutics' major shareholders?

Kalaris Therapeutics' top institutional shareholders include Octagon Capital Advisors LP (1.93%), Gilead Sciences Inc. (1.70%) and XTX Topco Ltd (0.13%).

How do I buy shares of Kalaris Therapeutics?

Shares of KLRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/13/2025
• Today: 9/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KLRS
• CIK: 1754068
• Web: N/A
• Phone: (617) 433-2605
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Kalaris Therapeutics: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: -29.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$58.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -81.02%
• Return on Assets: -65.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.98
• Quick Ratio: 11.98

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $22.47 per share
• Price / Book: 0.19

Miscellaneous

• Outstanding Shares: 18,700,000
• Free Float: 4,677,000
• Market Cap: $80.04 million
• Optionable: N/A
• Beta: 0.37